PUBLIC LIBRARY / SCORE

IPI (International Prognostic Index)

Classifies prognosis in adults with aggressive non-Hodgkin lymphoma (such as diffuse large B-cell lymphoma) at diagnosis, before treatment.

Calculate with transparency

Check the population, units and version. The result shows the formula or classification; it does not make an automatic treatment decision.

Preparing the form…

Check the method
Enter the data
Check the result

Method · Limits of application

International Prognostic Index 1993: 5 factors, 0–5; not NCCN-IPI or R-IPI

A classic prognostic index for adults with aggressive non-Hodgkin lymphoma, developed before treatment in historical doxorubicin cohorts. Distinguish classic IPI, age-adjusted IPI, R-IPI and NCCN-IPI. Historical probabilities do not demonstrate calibration for all subtypes or current treatments.

Conditions of use

Check the population, units, inclusion and exclusion criteria, and version in the original source. A result alone does not establish a diagnosis, discharge decision or prescription.

Documented parameters

Age > 60 years
Serum LDH above the upper limit of normal
ECOG ≥ 2
Ann Arbor stage III or IV
More than 1 extranodal site

4/4 reference cases checked. Numerical tests are not clinical validation.

Sources and documentation

Documented formula

Transcribed from the source or a recorded revision; this is not a clinical recommendation.

One point for each factor: age > 60 years · elevated LDH · ECOG ≥ 2 · stage III or IV · more than 1 extranodal site. Maximum: 5.

References

The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 1993.

Identifier: ipi-linfoma

Original clinical content: Brazilian Portuguese.

Method version

International Prognostic Index 1993: 5 factors, 0–5; not NCCN-IPI or R-IPI

ipi-linfoma@native-2026-10-03+7bf0f83fed1b

Source for the active edition

The bibliographic edition identifies the source. By itself, it proves neither full conformity of the formula nor clinical approval.

Synthetic cases checked (4)

Synthetic cases for checking the implementation, with no patient data.

Case 1

reference-001

Inputs

Age > 60 years: No
Serum LDH above the upper limit of normal: No
ECOG ≥ 2: No
Ann Arbor stage III or IV: No
More than 1 extranodal site: No

{
  "idade": false,
  "ldh": false,
  "ecog": false,
  "estadio": false,
  "extranodal": false
}

Expected result

{
  "score": 0,
  "level": "low"
}

Actual result

{
  "score": 0
}

Case 2

reference-002

Inputs

Age > 60 years: Yes
Ann Arbor stage III or IV: Yes
Serum LDH above the upper limit of normal: Yes
ECOG ≥ 2: No
More than 1 extranodal site: No

{
  "idade": true,
  "estadio": true,
  "ldh": true,
  "ecog": false,
  "extranodal": false
}

Expected result

{
  "score": 3,
  "level": "high",
  "verdict": "alto-intermediário"
}

Actual result

{
  "score": 3
}

Case 3

reference-003

Inputs

Serum LDH above the upper limit of normal: Yes
Ann Arbor stage III or IV: Yes
Age > 60 years: No
ECOG ≥ 2: No
More than 1 extranodal site: No

{
  "ldh": true,
  "estadio": true,
  "idade": false,
  "ecog": false,
  "extranodal": false
}

Expected result

{
  "score": 2,
  "level": "mid"
}

Actual result

{
  "score": 2
}

Case 4

reference-004

Inputs

Age > 60 years: Yes
Serum LDH above the upper limit of normal: Yes
ECOG ≥ 2: Yes
Ann Arbor stage III or IV: Yes
More than 1 extranodal site: Yes

{
  "idade": true,
  "ldh": true,
  "ecog": true,
  "estadio": true,
  "extranodal": true
}

Expected result

{
  "score": 5,
  "verdict": "Risco alto"
}

Actual result

{
  "score": 5
}

Code and reproducibility

This tool’s code on GitHub

Download code and tests

Sources, version and reproduction instructions

The code tests are technical checks. Clinical approval and professional translation review are recorded separately.

Relationship with cancer research

Specific oncological application

A prognostic index for aggressive lymphomas. Subtype, treatment and validation era must correspond to the study.

Applications: Survival and quality of life